Rasilez HCT(R) Receives Recommendation For European Approval As A Single-pill Combination To Treat High Blood Pressure

Rasilez HCT® (aliskiren and hydrochlorothiazide) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization as a new treatment for high blood pressure. Rasilez HCT is a single-pill combination of two high blood pressure medicines - first-in-class direct renin inhibitor Rasilez®[1] (aliskiren) and the diuretic hydrochlorothiazide (HCT).

More: continued here

Filed under: Hypertension on November 25th, 2008